Novel predictive assay for contact allergens using human skin explant cultures.
Contact allergens sensitize the immune system by the binding to and subsequent activation of Langerhans cells (LCs), the antigen-presenting cells of the skin. At present, new chemicals are usually tested for their contact allergenicity in animal models. To develop an animal-replacing predictive in vivo assay for the identification of potential contact allergens, we compared the effects of epicutaneous application of six known contact allergens, five known irritants and two dermatologically inactive chemicals on LCs in skin biopsy cultures from seven healthy donors. Immunohistochemical analysis of cryostat sections of all the biopsies treated with contact allergens showed 1) a large reduction in the number of LCs in epidermis, as evaluated by a decrease in human leukocyte antigens (HLA)-DR-expressing cells, and CD1a-expressing cells and 2) accumulation of the remaining LCs at the epidermal-dermal junction. In contrast, the irritants, inactive chemicals, and solvents did not induce these changes. Morphometrical analysis indicated that the contact allergen-induced reduction in the number of HLA-DR+ and CD1a+ LCs per millimeter of epidermis was significant and was dependent on the concentration of the contact allergens. Flow cytometric analysis of isolated epidermal cells confirmed the immunohistochemical findings. In combination, these results suggest that the culture of ex vivo human skin explants provides a promising model to predict potential allergenicity of newly produced chemical compounds and can therefore replace current animal models.
Pistoor
F H
FH
Department of Dermatology, Academic Medical Centre, University of Amsterdam, The Netherlands.
Rambukkana
A
A
Kroezen
M
M
Lepoittevin
J P
JP
Bos
J D
JD
Kapsenberg
M L
ML
Das
P K
PK
D000485:Allergens / Q000009:adverse effects*; D018949:Antigens, CD1 / Q000032:analysis / Q000187:drug effects*; D001681:Biological Assay / Q000379:methods*; D002452:Cell Count / Q000187:drug effects; D003877:Dermatitis, Contact / Q000276:immunology*; D004139:Dinitrofluorobenzene / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004817:Epidermis / Q000187:drug effects; D005434:Flow Cytometry; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D007509:Irritants / Q000009:adverse effects*; D007801:Langerhans Cells / Q000737:chemistry / Q000187:drug effects* / Q000276:immunology; D009532:Nickel / Q000009:adverse effects; D009924:Organ Culture Techniques; D011192:Potassium Dichromate / Q000009:adverse effects; D012867:Skin / Q000737:chemistry / Q000187:drug effects* / Q000276:immunology
D000485:Allergens; D018949:Antigens, CD1; D006684:HLA-DR Antigens; D007509:Irritants; C029938:nickel sulfate; D009532:Nickel; D004139:Dinitrofluorobenzene; D011192:Potassium Dichromate